TLIS (Talis Biomedical) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Talis Biomedical is: No Data: Cannot be evaluated.

Competitive Comparison of Talis Biomedical's Risk Assessment

For the Medical Devices subindustry, Talis Biomedical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talis Biomedical's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Talis Biomedical (OTCPK:TLIS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Talis Biomedical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Talis Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (OTCPK:TLIS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607

Website

https://talisbio.com

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

Executives

Andrew A Lukowiak	officer: President, other: Chief Scientific Officer	1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich	officer: Interim CFO	CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser	director, officer: President and CEO	561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan	officer: Sr. Vice President, R&D	230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Moody John Roger Jr	officer: Chief Financial Officer	4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062